Transforming growth factor-β: What every pancreatic surgeon should know

Surgery

Volumn 141, Issue 1, 2007, Pages 1-6

  Truty, Mark J ^a   Urrutia, Raul ^b  

^a Mayo Clinic   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS DNA; CYTOKINE; MEMBRANE PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CANCER IMMUNOLOGY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; EXTRACELLULAR MATRIX; FIBROSIS; GENE MUTATION; GENETIC TRANSCRIPTION; GROWTH INHIBITION; HUMAN; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE; WOUND HEALING;

EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MODELS, BIOLOGICAL; PANCREAS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS; WOUND HEALING;

EID: 33845502537     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2006.07.019     Document Type: Review

References (44)

1. Anzano M.A., Roberts A.B., Smith J.M., et al. Sarcoma growth factor from conditioned medium of virally transformed cells is composed of both type alpha and type beta transforming growth factors. Proc Natl Acad Sci U S A 80 (1983) 6264-6268
2. Derynck R., Akhurst R.J., and Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29 (2001) 117-129
3. Frank D.A. TGF-beta signaling alteration in cancer. Signal transduction in cancer (2003), Kluwer Academic Publishers, Norwell (MA) 73-94
4. Massague J. TGF-beta signal transduction. Annu Rev Biochem 67 (1998) 753-791
5. Massague J., and Chen Y.G. Controlling TGF-beta signaling. Genes Dev 14 (2000) 627-644
6. Suzuki C., Murakami G., Fukuchi M., et al. Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 277 (2002) 39919-39925
7. Wotton D., Lo R.S., Lee S., and Massague J. A Smad transcriptional corepressor. Cell 97 (1999) 29-39
8. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signaling. Nature 425 (2003) 577-584
9. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
10. Bertino J.R. Encyclopedia of Cancer Vol. 1 (2002), Elsevier, San Diego (CA) 393-404
11. Seoane J., Le H.V., Shen L., et al. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117 (2004) 211-223
12. Alvarez C.B.B. Role of transforming growth factor-beta in growth and injury response of the pancreatic duct epithelium in vitro. J Gastrointest Surg 3 (1999) 178-184
13. Tachibana I., Imoto M., Adjei P.N., et al. Overexpression of the TGF-beta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells. J Clin Invest 99 (1997) 2365-2374
14. Tanigawa T., Pai R., Arakawa T., et al. TGF-beta signaling pathway: its role in gastrointestinal pathophysiology and modulation of ulcer healing. J Physiol Pharmacol 56 (2005) 3-13
15. Kane C.J., Hebda P.A., Mansbridge J.N., and Hanawalt P.C. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J Cell Physiol 148 (1991) 157-173
16. Wahl S.M., Hunt D.A., Wakefield L.M., et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 84 (1987) 5788-5792
17. Mustoe T.A., Pierce G.F., Thomason A., et al. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science 237 (1987) 1333-1336
18. Grande J.P. Role of transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 214 (1997) 27-40
19. Mustoe T.A., Landes A., Cromack D.T., et al. Differential acceleration of healing of surgical incisions in the rabbit gastrointestinal tract by platelet-derived growth factor and transforming growth factor, type beta. Surgery 108 (1990) 324-329 discussion 329-30
20. Chen S.J., Yuan W., Mori Y., et al. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-beta: involvement of Smad 3. J Invest Dermatol 112 (1999) 49-57
21. Lin R.Y., Sullivan K.M., Argenta P.A., et al. Exogenous transforming growth factor-beta amplifies its own expression and induces scar formation in a model of human fetal skin repair. Ann Surg 222 (1995) 146-154
22. Fukumura Y., Kumasaka T., Mitani K., et al. Expression of transforming growth factor beta1, beta2, and beta3 in chronic, cancer-associated, obstructive pancreatitis. Arch Pathol Lab Med 130 (2006) 356-361
23. Friess H., Kleeff J., Korc M., and Buchler M.W. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg 16 (1999) 281-290
24. Wagner M., Kleeff J., Lopez M.E., et al. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. Int J Cancer 78 (1998) 255-260
25. Hahn S.A., Hoque A.T., Moskaluk C.A., et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res 56 (1996) 490-494
26. Hahn S.A., Schutte M., Hoque A.T., et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271 (1996) 350-353
27. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Probl Cancer 26 (2002) 176-275
28. Furukawa T., Sunamura M., and Horii A. Molecular mechanisms of pancreatic carcinogenesis. Cancer Sci 97 (2006) 1-7
29. Hansel D.E., Kern S.E., and Hruban R.H. Molecular pathogenesis of pancreatic cancer. Annu Rev Genomics Hum Genet 4 (2003) 237-256
30. Elliott R.L., and Blobe G.C. Role of transforming growth factor Beta in human cancer. J Clin Oncol 23 (2005) 2078-2093
31. Siegel P.M., and Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3 (2003) 807-821
32. Baldwin R.L., Friess H., Yokoyama M., et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 67 (1996) 283-288
33. Pasche B., Kolachana P., Nafa K., et al. TbetaR-I(6A) is a candidate tumor susceptibility allele. Cancer Res 59 (1999) 5678-5682
34. Kuang C., Xiao Y., Liu X., et al. In vivo disruption of TGF-beta signaling by Smad7 leads to premalignant ductal lesions in the pancreas. Proc Natl Acad Sci U S A 103 (2006) 1858-1863
35. Ito D., Fujimoto K., Doi R., et al. Chronic exposure of transforming growth factor beta-1 confers a more aggressive tumor phenotype through downregulation of p21(WAF1/CIP1) in conditionally immortalized pancreatic epithelial cells. Surgery 136 (2004) 364-374
36. Bellone G., Smirne C., Mauri F.A., et al. Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival. Cancer Immunol Immunother 55 (2006) 684-698
37. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression by TGF-beta inhibitors. Invest New Drugs 21 (2003) 21-32
38. Bellone G., Turletti A., Artusio E., et al. Tumor-associated transforming growth factor-beta and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am J Pathol 155 (1999) 537-547
39. von Bernstorff W., Voss M., Freichel S., et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7 3 Suppl (2001) 925-932
40. Mizoguchi H., O'Shea J.J., Longo D.L., et al. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258 (1992) 1795-1798
41. Brunner N., Pyke C., Hansen C.H., et al. Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Cancer Treat Res 71 (1994) 299-309
42. Reuning U., Magdolen V., Wilhelm O., et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 13 (1998) 893-906
43. Ellenrieder V., Hendler S.F., Ruhland C., et al. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 93 (2001) 204-211
44. Ellenrieder V., Hendler S.F., Boeck W., et al. Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61 (2001) 4222-4228